论文部分内容阅读
目的:采用meta分析比较放疗联合表皮生长因子受体酪氨酸激酶抑制剂与放疗联合化疗治疗非小细胞肺癌脑转移的疗效及安全性。方法:检索Web of Science、Embase、PubMed、万方、维普中文科技期刊数据库、中国期刊全文数据库、中国知网等电子数据库。检索时限截至2019年10月22日。按纳排标准筛选出目标文献，试验组为放疗联合靶向治疗，对照组为放疗联合化疗。采用纽卡斯尔-渥太华量表对文献进行质量评价，通过R语言进行统计分析，对研究的客观缓解率、疾病控制率、1年生存率、无进展生存期、总生存期和不良反应等进行评估，对各研究结果进行数据合并，计算合并后的95%n CI，对各研究结果进行敏感性分析，评价meta分析结果的稳定性。n 结果:最终共纳入了10篇回顾性研究文献，共计839例非小细胞肺癌脑转移患者。治疗方面，试验组客观缓解率(65.69%，n OR＝4.19，95%n CI：3.07～5.73，n P<0.000 1)、疾病控制率(85.29%，n OR＝3.42，95%n CI：2.28～5.12，n P<0.000 1)、1年生存率(66.18%，n OR＝1.52，95%n CI：1.05～2.19，n P＝0.026)均高于对照组。不良反应方面，试验组骨髓抑制发生率低于对照组，皮疹发生率高于对照组，差异均有统计学意义(n P值均0.05)。n 结论:meta分析显示放疗联合靶向治疗非小细胞肺癌脑转移优于放疗联合化疗，可提高临床疗效，改善1年生存率，骨髓抑制的不良反应发生率更低，皮疹发生率更高，消化系统及肝功能损害的不良反应发生无明显差异。“,”Objective:To compare the safety and efficacy of radiotherapy combined with epidermal growth factor receptor tyrosine kinase inhibitor and radiotherapy combined with chemotherapy in the treatment of brain metastasis of non-small cell lung cancer by meta-analysis.Methods:A literature search was conducted among Web of Science, Embase, PubMed, Wanfang, VIP Chinese science and technology journal database, China Journal Full-text Database, CNKI and other electronic database.The retrieval deadline is October 22, 2019.According to the inclusion and exclusion criteria, the research literature was selected.The Newcastle Ottawa scale was assessed to evaluate the quality of the literature.The objective remission rate, disease control rate, 1-year survival rate, progression free survival, overall survival and adverse reactions of the study were evaluated by R-language statistical analysis.The data of each study were combined to calculate the 95% n CI.The sensitivity of each study was analyzed to evaluate the meta-analysis results stability.n Results:A total of 839 patients were included in 10 literatures.In terms of treatment, the objective remission rate (65.69%, n OR=4.19, 95%n CI: 3.07-5.73, n P<0.000 1), disease control rate (85.29%,n OR=3.42, 95%n CI: 2.28-5.12, n P<0.000 1) and 1-year survival rate (66.18%,n OR=1.52, 95%n CI: 1.05-2.19, n P=0.026) of the experimental group were higher than those of the control group.In terms of adverse reactions, the incidence of bone marrow suppression in the experimental group was lower than that in control group, and the incidence of rash was higher than that in control group, the differences were statistically significant (all n P0.05).n Conclusions:Meta analysis showed that radiotherapy combined with targeted therapy was better than radiotherapy combined with chemotherapy in the treatment of brain metastasis of non-small cell lung cancer, which could improve the clinical efficacy and 1-year survival rate.The incidence of adverse reactions of hematological myelosuppression is lower, the incidence of rash is higher, and there is no significant difference in adverse reactions of digestive system and liver function damage.